BR112021023522A8 - Composto ou um sal, tautômero, solvato ou estereoisômero farmaceuticamente aceitável deste, composição farmacêutica, processo para a síntese do composto e uso do composto - Google Patents
Composto ou um sal, tautômero, solvato ou estereoisômero farmaceuticamente aceitável deste, composição farmacêutica, processo para a síntese do composto e uso do compostoInfo
- Publication number
- BR112021023522A8 BR112021023522A8 BR112021023522A BR112021023522A BR112021023522A8 BR 112021023522 A8 BR112021023522 A8 BR 112021023522A8 BR 112021023522 A BR112021023522 A BR 112021023522A BR 112021023522 A BR112021023522 A BR 112021023522A BR 112021023522 A8 BR112021023522 A8 BR 112021023522A8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- tautomer
- stereoisomer
- solvate
- synthesis
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 9
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000012453 solvate Substances 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- 241000700721 Hepatitis B virus Species 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
COMPOSTO OU UM SAL, TAUTÔMERO, SOLVATO OU ESTEREOISÔMERO FARMACEUTICAMENTE ACEITÁVEL DESTE, COMPOSIÇÃO FARMACÊUTICA, PROCESSO PARA A SÍNTESE DO COMPOSTO E USO DO COMPOSTO. A presente invenção se refere a compostos que são inibidores do vírus da hepatite B (HBV). Os compostos da presente invenção são úteis sozinhos ou em combinação com outros agentes para o tratamento, melhora, prevenção ou cura da infecção pelo HBV e condições relacionadas. A presente invenção também se refere a composições farmacêuticas contendo os ditos compostos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19176238.4A EP3741762A1 (en) | 2019-05-23 | 2019-05-23 | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus |
EP19211249.8A EP3825318A1 (en) | 2019-11-25 | 2019-11-25 | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus |
PCT/EP2020/064424 WO2020234483A1 (en) | 2019-05-23 | 2020-05-25 | Oxalamido-substituted tricyclic inhibitors of hepatitis b virus |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112021023522A2 BR112021023522A2 (pt) | 2022-01-25 |
BR112021023522A8 true BR112021023522A8 (pt) | 2022-10-18 |
Family
ID=70802873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021023522A BR112021023522A8 (pt) | 2019-05-23 | 2020-05-25 | Composto ou um sal, tautômero, solvato ou estereoisômero farmaceuticamente aceitável deste, composição farmacêutica, processo para a síntese do composto e uso do composto |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220241241A1 (pt) |
EP (1) | EP3972979A1 (pt) |
JP (1) | JP2022533462A (pt) |
KR (1) | KR20220034049A (pt) |
CN (1) | CN114555608A (pt) |
AU (1) | AU2020278909A1 (pt) |
BR (1) | BR112021023522A8 (pt) |
CA (1) | CA3139816A1 (pt) |
CL (1) | CL2021003099A1 (pt) |
CO (1) | CO2021016830A2 (pt) |
IL (1) | IL288188A (pt) |
MX (1) | MX2021014095A (pt) |
SG (1) | SG11202112345QA (pt) |
TW (1) | TW202110857A (pt) |
UY (1) | UY38705A (pt) |
WO (1) | WO2020234483A1 (pt) |
ZA (1) | ZA202109005B (pt) |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040097492A1 (en) * | 2002-11-01 | 2004-05-20 | Pratt John K | Anti-infective agents |
GB0522881D0 (en) * | 2005-11-10 | 2005-12-21 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
ES2378513T3 (es) | 2008-08-06 | 2012-04-13 | Pfizer Inc. | Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1 |
CN103889953B (zh) | 2011-07-01 | 2016-06-08 | 巴鲁﹒S﹒布隆伯格研究所 | 作为防乙型肝炎病毒感染的抗病毒剂的氨磺酰苯甲酰胺衍生物 |
KR20190007106A (ko) | 2011-12-21 | 2019-01-21 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
CA2862755A1 (en) * | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
WO2014106019A2 (en) | 2012-12-27 | 2014-07-03 | Philadelphia Health & Education Corporation, D/B/A Drexel | Novel antiviral agents against hbv infection |
US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
JP6452119B2 (ja) * | 2013-10-23 | 2019-01-16 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カルボキサミド誘導体およびb型肝炎の処置のための医薬品としてのその使用 |
US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
EP3102225B1 (en) | 2014-02-05 | 2020-03-25 | Novira Therapeutics Inc. | Combination therapy for treatment of hbv infections |
US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
EP3227262B1 (en) | 2014-12-02 | 2020-05-13 | Novira Therapeutics Inc. | Sulfide alkyl and pyridyl reverse sulfonamide compounds for hbv treatment |
US9597332B2 (en) | 2014-12-02 | 2017-03-21 | Novira Therapeutics, Inc. | Sulfide alkyl compounds for HBV treatment |
CA2972434A1 (en) * | 2014-12-30 | 2016-07-07 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis b infections |
US9765050B2 (en) | 2014-12-30 | 2017-09-19 | Novira Therapeutics, Inc. | Pyridyl reverse sulfonamides for HBV treatment |
US10875876B2 (en) * | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
DK3331886T3 (da) | 2015-08-05 | 2020-08-24 | Indivior Uk Ltd | Dopamin-d3-receptorantagonister med en bicyclo-del |
CN107759585A (zh) * | 2016-07-29 | 2018-03-06 | 银杏树药业(苏州)有限公司 | 一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用 |
EP3608326A1 (en) | 2018-08-10 | 2020-02-12 | Irbm S.P.A. | Tricyclic inhibitors of hepatitis b virus |
-
2020
- 2020-05-21 UY UY0001038705A patent/UY38705A/es unknown
- 2020-05-22 TW TW109117176A patent/TW202110857A/zh unknown
- 2020-05-25 MX MX2021014095A patent/MX2021014095A/es unknown
- 2020-05-25 US US17/611,777 patent/US20220241241A1/en active Pending
- 2020-05-25 JP JP2021569945A patent/JP2022533462A/ja active Pending
- 2020-05-25 EP EP20727641.1A patent/EP3972979A1/en active Pending
- 2020-05-25 CN CN202080052973.3A patent/CN114555608A/zh active Pending
- 2020-05-25 CA CA3139816A patent/CA3139816A1/en active Pending
- 2020-05-25 BR BR112021023522A patent/BR112021023522A8/pt unknown
- 2020-05-25 WO PCT/EP2020/064424 patent/WO2020234483A1/en unknown
- 2020-05-25 SG SG11202112345QA patent/SG11202112345QA/en unknown
- 2020-05-25 AU AU2020278909A patent/AU2020278909A1/en active Pending
- 2020-05-25 KR KR1020217041588A patent/KR20220034049A/ko active Search and Examination
-
2021
- 2021-11-12 ZA ZA2021/09005A patent/ZA202109005B/en unknown
- 2021-11-17 IL IL288188A patent/IL288188A/en unknown
- 2021-11-23 CL CL2021003099A patent/CL2021003099A1/es unknown
- 2021-12-13 CO CONC2021/0016830A patent/CO2021016830A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN114555608A (zh) | 2022-05-27 |
TW202110857A (zh) | 2021-03-16 |
WO2020234483A1 (en) | 2020-11-26 |
SG11202112345QA (en) | 2021-12-30 |
CO2021016830A2 (es) | 2022-04-29 |
CA3139816A1 (en) | 2020-11-26 |
MX2021014095A (es) | 2022-02-21 |
BR112021023522A2 (pt) | 2022-01-25 |
CL2021003099A1 (es) | 2022-08-26 |
EP3972979A1 (en) | 2022-03-30 |
JP2022533462A (ja) | 2022-07-22 |
KR20220034049A (ko) | 2022-03-17 |
AU2020278909A1 (en) | 2021-12-23 |
ZA202109005B (en) | 2022-08-31 |
US20220241241A1 (en) | 2022-08-04 |
IL288188A (en) | 2022-01-01 |
UY38705A (es) | 2020-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018075465A2 (pt) | agentes antivirais de hepatite b | |
BR112018067964A2 (pt) | agentes antivirais para hepatite b | |
BRPI0516972A (pt) | composto, uso do mesmo, composição farmacêutica, método para inibir a polimerase do vìrus da hepatite c e/ou de tratar ou prevenir uma doença devido ao vìrus da hepatite c, e, processo para preparar um composto | |
BR112022004248A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer | |
BR112021024674A2 (pt) | Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
BRPI0612104A8 (pt) | composto, mistura diastereomérica, composição farmacêutica, e, método para tratar infecções por hepatite c em um paciente e para tratar infecções por hcv em um paciente | |
UY37998A (es) | Agentes antivirales contra la hepatitis b | |
BRPI0608245A2 (pt) | compostos; processo para a sua fabricação; composições farmacêuticas; método para o tratamento e/ou prevenção de doenças que estejam associadas à modulação de receptores de sst subtipo 5 e uso dos compostos | |
CL2008002995A1 (es) | Compuestos derivados de espiropirrolidina; composicion farmaceutica que los comprende; procedimiento de preparacion de compuestos intermediarios; y su uso para tratar la infeccion del virus de la hepatitis c y del vih. | |
BRPI0511283A (pt) | aril aciltiouréias substituìdas e compostos relacionados; inibidores da replicação viral | |
BR112012014899A2 (pt) | composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus | |
BR112012003578A8 (pt) | Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal | |
BR112012018529A2 (pt) | inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna | |
BR112021002565A8 (pt) | Composto, sal farmaceuticamente aceitável, tautômero ou estereoisômero do mesmo, composição farmacêutica, processo para a síntese e uso do dito composto | |
BRPI0513858B8 (pt) | compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende | |
AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
CL2008000959A1 (es) | Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c. | |
BR112014010401A2 (pt) | inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina | |
MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
CL2021002390A1 (es) | Derivados de pirimidona de anillo fusionado para su uso en el tratamiento de la infección por vhb (virus hepatitis b) o de enfermedades inducidas por el vhb. | |
CL2021001629A1 (es) | Compuestos de halo-alilamina y uso de los mismos | |
BR112014001083A8 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto | |
BR112022002496A2 (pt) | Compostos deuterados para uso no tratamento de câncer | |
CO2023017300A2 (es) | Compuestos moduladores de diacilglicerol quinasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: ANTIOS THERAPEUTICS, INC. (US) |
|
B25C | Requirement related to requested transfer of rights |
Owner name: ANTIOS THERAPEUTICS, INC. (US) Free format text: A FIM DE ATENDER A TRANSFERENCIA REQUERIDA ATRAVES DA PETICAO 870230031109 DE 13/04/2023 E NECESSARIO GRU 248 PARA ALTERACAO DE SEDE DO DEPOSITANTE ?ANTIOS THERAPEUTICS, INC.? PELA DIVERGENCIA ENTRE O ATUAL ENDERECO E O CONSTANTE NO DOCUMENTO DE CESSAO. |
|
B25G | Requested change of headquarter approved |
Owner name: ANTIOS THERAPEUTICS, INC. (US) |
|
B25A | Requested transfer of rights approved |
Owner name: OSPEDALE SAN RAFFAELE S.R.L. (IT) ; ISTITUTO NAZIONALE DI GENETICA MOLECOLARE - INGM (IT) ; IRBM S.P.A. (IT) |